143 related articles for article (PubMed ID: 37029241)
41. A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients.
Due A; Berg T; Jensen MB; Yammeni S; Volmer L; Brems-Eskildsen AS; Andersen KK; Rana S; Knoop A; Kümler I
Acta Oncol; 2023 Feb; 62(2):126-133. PubMed ID: 36929759
[TBL] [Abstract][Full Text] [Related]
42. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Palumbo A; Lau G; Saraceni M
Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
[TBL] [Abstract][Full Text] [Related]
43. Abemaciclib for the Treatment of HR+HER2- Metastatic Breast Cancer: An Institutional Experience.
Matos E; Cankar K; Režun N; Dejanović K; Ovčariček T
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791907
[TBL] [Abstract][Full Text] [Related]
44. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
45. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
[TBL] [Abstract][Full Text] [Related]
46. Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre.
Twelves C; Cheeseman S; Sopwith W; Thompson M; Riaz M; Ahat-Donker N; Myland M; Lee A; Przybysz R; Turner S; Hall G; Perren T
BMC Cancer; 2020 Jan; 20(1):53. PubMed ID: 31964373
[TBL] [Abstract][Full Text] [Related]
47. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.
Cobleigh M; Yardley DA; Brufsky AM; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Hurvitz SA; O'Shaughnessy J; Mason G; Antao V; Li H; Chu L; Jahanzeb M
Clin Cancer Res; 2020 Mar; 26(5):1105-1113. PubMed ID: 31772121
[TBL] [Abstract][Full Text] [Related]
48. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR
Dickler MN; Tolaney SM; Rugo HS; Cortés J; Diéras V; Patt D; Wildiers H; Hudis CA; O'Shaughnessy J; Zamora E; Yardley DA; Frenzel M; Koustenis A; Baselga J
Clin Cancer Res; 2017 Sep; 23(17):5218-5224. PubMed ID: 28533223
[No Abstract] [Full Text] [Related]
49. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
[TBL] [Abstract][Full Text] [Related]
50. Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR
Brufsky A; Mitra D; Davis KL; Nagar SP; McRoy L; Cotter MJ; Stearns V
Clin Breast Cancer; 2019 Oct; 19(5):317-325.e4. PubMed ID: 31104984
[TBL] [Abstract][Full Text] [Related]
51. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
[TBL] [Abstract][Full Text] [Related]
52. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
Wood R; Mitra D; de Courcy J; Iyer S
Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
[TBL] [Abstract][Full Text] [Related]
53. Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer.
Goyal RK; Carter GC; Nagar SP; Smyth EN; Price GL; Huang YJ; Li L; Davis KL; Kaye JA
Curr Med Res Opin; 2019 Oct; 35(10):1699-1710. PubMed ID: 31060392
[No Abstract] [Full Text] [Related]
54. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
Martin M; Hegg R; Kim SB; Schenker M; Grecea D; Garcia-Saenz JA; Papazisis K; Ouyang Q; Lacko A; Oksuzoglu B; Reeves J; Okera M; Testa L; Shimizu C; Denduluri N; Adamchuk H; Dakhil S; Wei R; Forrester T; Fernandez MM; Zimmermann A; Headley D; Johnston SRD
JAMA Oncol; 2022 Aug; 8(8):1190-1194. PubMed ID: 35653145
[TBL] [Abstract][Full Text] [Related]
55. Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer.
Miyahara K; Narui K; Uemura Y; Yamada A; Araki K; Fujisawa F; Nakayama T; Ishikawa T; Taira N; Kikawa Y; Aihara T; Mukai H
World J Oncol; 2022 Aug; 13(4):216-221. PubMed ID: 36128594
[TBL] [Abstract][Full Text] [Related]
56. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
57. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
[TBL] [Abstract][Full Text] [Related]
58. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
[TBL] [Abstract][Full Text] [Related]
59. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
[TBL] [Abstract][Full Text] [Related]
60. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]